6. Conclusions

In this focused revision of the CCS guidelines for the management of dyslipidemia, the committee has distilled several years of new research in CV risk assessment (especially as it pertains to women), lipoprotein biomarkers, and coronary artery calcium scanning. The committee also reviewed several major landmark RCTs of novel therapies to treat dyslipidemia. On the basis of the best available evidence to date, we have developed several new recommendations for clinicians to more accurately assess their patients’ CV risk and optimally manage their lipid disorders. We acknowledge that the science surrounding CV risk and dyslipidemia management is evolving and therefore these recommendations can only be viewed as the best practices on the basis of the currently available evidence. Nonetheless, the objective of any guideline is to provide clinicians with the most up-to-date knowledge and tools to help them make informed decisions with their patients. Appendix 1 provides an at-a-glance, step-wise summary of the management of adult patients with dyslipidemia for the prevention of cardiovascular disease, based on the 2021 CCS dyslipidemia guidelines. The past few years has realized significant progress in the management of dyslipidemia, with several new therapies currently available and more in development. With continued efforts to prioritize healthy lifestyles and the use of new pharmacotherapeutic options available to treat eligible patients, we hope to realize further reductions in morbidity and mortality from ASCVD in Canada.